Abstral is a rapid dissolving, sub-lingual tablet of fentanyl, indicated for the management of breakthrough cancer pain in patients who are already receiving opioid analgesics. Abstral is currently approved in Sweden, Denmark, UK and Germany.
Sancuso is a transdermal patch that delivers granisetron, an established 5HT3 receptor antagonist, and is indicated for the prevention of nausea and vomiting in patients undergoing chemotherapy for up to five consecutive days.
Jonathan Goodman, president and CEO of Paladin Labs, said: “It is our intention to submit these two innovative products for Canadian regulatory approval in mid-2009. We expect Abstral and Sancuso to fulfill an unmet need for cancer patients in Canada.
“These products complement our dynamic and growing promoted pain portfolio, which already includes Tridural, Metadol and Pennsaid, and provides us an additional pillar upon which to build out a supportive care oncology franchise.”